Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as an oral formulation for prescription use. It is employed in the management of severe psoriasis and related disorders of keratinization, acting on patients who require systemic therapy after topical measures have proved insufficient.

GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neotigason (acetretin) is used within the retinoid class to treat disorders of epidermal proliferation and differentiation.

- Severe psoriasis: reduces plaque thickness, scaling and erythema. - Psoriatic keratoderma: improves hyperkeratotic lesions on palms and soles. - Disorders of keratinization: normalises abnormal skin cell turnover in conditions such as ichthyosis.

Acitretin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dry skin and mucous membranes. - Cheilitis (cracked lips). - Hair thinning or loss. - Elevated triglyceride levels. - Headache or mild nausea. - Itching or rash.

Serious or Rare Side Effects: - Hepatotoxicity (liver enzyme elevation). - Severe hyperlipidaemia. - Pseudotumor cerebri (increased intracranial pressure). - Bone demineralisation or fractures. - Severe allergic reactions (e.g., Stevens‑Johnson syndrome). - Teratogenic effects (birth defects).

Before initiating therapy, clinicians should evaluate several safety parameters.

- Pregnancy contraindication: avoid use in women of childbearing potential; effective contraception required. - Liver function: monitor hepatic enzymes regularly. - Lipid profile: check triglycerides and cholesterol before and during treatment. - Vitamin A supplementation: discontinue to prevent additive toxicity. - Concomitant tetracyclines: avoid due to risk of intracranial hypertension. - Store at room temperature: keep in the original container, protect from moisture and light.

Acitretin can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Vitamin A or other retinoids: additive teratogenic and toxicity risk. - Tetracycline antibiotics: increased risk of pseudotumor cerebri. - Systemic corticosteroids: may exacerbate bone loss.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced effectiveness, consider alternative contraception. - Warfarin: potential alteration of anticoagulant effect. - Statins: possible increase in lipid abnormalities. - Methotrexate: enhanced hepatotoxic potential when combined.